Abstract: A 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal and its use as an opioid antagonist are disclosed. The invention also relates to a drug-in-adhesive transdermal patch containing the analgesic fentanyl, a mu opioid agonist, or an analog thereof and a 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal, as an opioid antagonist. A transdermal patch of the invention is tamper-resistant and an abuse deterrent which protects against drug misuse or abuse. The invention also provides a method of treating pain, such as acute, chronic, or intermittent pain, by applying a drug-in-adhesive transdermal patch according to the invention to the skin of a patient in need thereof. Also disclosed is an improved transdermal patch for administering fentanyl or an analog thereof, or for administering a mu opioid agonist, the improvement wherein the transdermal patch contains a 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal in an abuse limiting amount.

Abstract: The present invention is based upon the finding that certain conditions, diseases and/or disorders affecting the skin, are associated with reduced expression of an enzyme exhibiting oxidoreductase activity. Accordingly, the invention provides oxidoreductase enzymes and/or genes encoding the same for use in treating or preventing disorders of the skin and method for generating Type VII collagen suitable for use in treating disorders of the skin.

Abstract: The disclosure relates to new crystalline forms of genistein. The disclosed crystalline forms include crystalline genistein sodium salt dihydrate; crystalline genistein potassium salt dihydrate; crystalline genistein calcium salt; crystalline genistein magnesium salt; crystalline genistein L-lysine salt; crystalline genistein N-methylglucamine salt; crystalline genistein N-ethylglucamine salt; crystalline genistein diethylamine salt; and crystalline genistein monohydrate. The disclosure also relates to the novel genistein salts represented by these crystalline forms. Therapeutic compositions containing at least one of these crystalline forms of genistein and/or a genistein salt and a pharmaceutically acceptable carrier are described.

Abstract: The disclosure relates to new crystalline forms of genistein. The disclosed crystalline forms include crystalline genistein sodium salt dihydrate; crystalline genistein potassium salt dihydrate; crystalline genistein calcium salt; crystalline genistein magnesium salt; crystalline genistein L-lysine salt; crystalline genistein N-methylglucamine salt; crystalline genistein N-ethylglucamine salt; crystalline genistein diethylamine salt; and crystalline genistein monohydrate. The disclosure also relates to the novel genistein salts represented by these crystalline forms. Therapeutic compositions containing at least one of these crystalline forms of genistein and/or a genistein salt and a pharmaceutically acceptable carrier are described.

Abstract: A local sewage processing unit is provided that receives sewage from a local source of sewage, extracts water from the received sewage that is suitable for re-use and includes a pump that is configured to pump sewage from a receiving section of the local sewage processing unit into a pressure sewer network, as required.

Abstract: The invention provides an adaptor for mounting a pump directly to the ink circulation system of an inkjet printer. By incorporating an adaptor and providing a selection of adaptors, a variety of pumps can be fitted to the ink circulation system without the need for pipes and pipe connectors.

Abstract: The present invention discloses a series of genes and/or proteins associated with cutaneous squamous cell carcinoma (cSCC) and provides polynucleotides and/or polypeptides for use in the treatment and/or prevention of cSCC. The invention further relates to methods of diagnosing cSCC and provides oligonucleotides/polypeptide probes and primers.

Abstract: The disclosure relates to new crystalline forms of genistein. The disclosed crystalline forms include crystalline genistein sodium salt dihydrate; crystalline genistein potassium salt dihydrate; crystalline genistein calcium salt; crystalline genistein magnesium salt; crystalline genistein L-lysine salt; crystalline genistein N-methylglucamine salt; crystalline genistein N-ethylglucamine salt; crystalline genistein diethylamine salt; and crystalline genistein monohydrate. The disclosure also relates to the novel genistein salts represented by these crystalline forms. Therapeutic compositions containing at least one of these crystalline forms of genistein and/or a genistein salt and a pharmaceutically acceptable carrier are described.

Abstract: The invention relates to a new crystalline form of tiotropium bromide, processes for preparing it and its use for preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.

Abstract: The disclosure relates to a new crystalline form of genistein. The disclosed crystalline form is crystalline genistein sodium salt dihydrate. The disclosure also relates to the novel genistein salt composition represented by this crystalline form. Therapeutic compositions containing crystalline genistein sodium salt and a pharmaceutically acceptable carrier are described. The disclosure also relates to therapeutic methods comprising the step of administering to a patient in need thereof a therapeutically effective amount of a therapeutic composition containing the crystalline form of the disclosure or crystalline genistein sodium salt dihydrate.

Abstract: A local sewage processing unit is provided that receives sewage from a local source of sewage, extracts water from the received sewage that is suitable for re-use and includes a pump that is configured to pump sewage from a receiving section of the local sewage processing unit into a pressure sewer network, as required.

Abstract: The disclosure relates to a new crystalline form of genistein. The disclosed crystalline form is crystalline genistein sodium salt dihydrate. The disclosure also relates to the novel genistein salt composition represented by this crystalline form. Therapeutic compositions containing crystalline genistein sodium salt and a pharmaceutically acceptable carrier are described. The disclosure also relates to therapeutic methods comprising the step of administering to a patient in need thereof a therapeutically effective amount of a therapeutic composition containing the crystalline form of the disclosure or crystalline genistein sodium salt dihydrate.

Abstract: A system, method, and medium for cadence management of translated multi-speaker conversations including a demultiplexer for separating a multi-speaker audio source into time-related single-speaker audio tracks, each track containing first language audio snippets; and a pause relationship model generator and manager that determines the time relationships between the single-speaker snippets using pause markers to denote beginnings and endings of mutual silence pauses, collects a translated language audio track for each of single-speaker track, transforms the original pause relationship model of the snippets, and controls a multiplexer to producing a multi-speaker audio output including the translated snippets in a manner such that they are related in time according to the transformed pause relationship model.

Abstract: A system, method, and software-encoded computer readable medium which receives an electronic streaming information resource, such as a multi-party audio conversation, determines demarcations between collective audio chunks (CAC) within the resource by determining when universal pauses (UP) exist across all party contributions; and submits the collective audio chunks in a substantially first-found, first-submitted order to a translation system. The collective audio chunks are then translated in real time, and the translated collective audio chunks are loaded into a real-time streaming buffer for delivery to one or more destinations.

Abstract: Polymorphs and pharmaceutical formulations of 17-allylamino-17-demethoxygeldanamycin (17-AAG).

Abstract: An auditing system is disclosed comprising a Policy Validation Mechanism Program (PVMP) that operates in conjunction with a Workflow Engine (WE), and a Policy Validation Server Program (PVSP) that operates on a Policy Validation Server (PVS) connected to the WE by a secure communication link. The PVMP converts a workflow to a workflow representation (WR) and sends the WR to the PVS. The PVSP compares the steps in the WR to a security policy identified for that WR and determines whether the WR is in compliance. In addition, the PVSP validates a checksum for the WR and logs the checksum for subsequent comparisons. The PVSP uses the checksum to determine whether a policy has changed during execution of the workflow. If the WR is not in compliance, if the checksum cannot be validated, or if a policy has changed, then a failure notification is sent to the WE. Otherwise, a success notification is sent to the WR.

Abstract: An ornamental lamp assembly incorporating a dual housing structure having an internal protective element and an external decorative element to protect functional circuitry from damage sustained as a result of normal outdoor use, and to facilitate achieving a selectively varied decor by interchanging the external decorative housing element with other external decorative housing elements having unique features.

Abstract: An integration server architecture (ISA) that facilitates communication between processes that do not share a common message format or use a common communication protocol. The ISA comprises a combination of adapters and a Queuing and Translation Engine (QTE). Every process that uses the ISA must have an adapter designed to understand that process's native message format. The adapter forwards the message to the QTE. The QTE places the forwarded message in an incoming message queue (IMQ). The QTE then retrieves messages from the IMQ in the order they arrive, identifies the sender, and locates an entry for the sender in a Configuration Database (CDB). The CDB entry designates a translation map that enables the QTE to properly translate messages into the receiving process's native format. The QTE uses the map to translate the messages into the receiving process's native format, and then forwards the translated message to the appropriate adapter.

Abstract: A container (1) is proposed for replenishing ink or solvent in an ink jet printer ink system. The container (1) has a plug-in connector (7) for attachment to a mating connector on the ink system along an axis so that fluid within the container (1) can be transferred to the ink system. Adjacent to the connector (7) a cam surface is disposed so as to cause the connector (7) to disconnect from the mating connector on rotation of the container (1) in a direction about the axis.